The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice

5,6-dimethylxanthenone-4-acetic acid, a novel antivascular anticancer drug, has completed Phase I clinical trial. Its actions in mice include tumour necrosis factor induction, serotonin release, tumour blood flow inhibition, and the induction of tumour haemorrhagic necrosis and regression. We have u...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, L, Ching, L-M, Kestell, P, Baguley, B C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376130/
https://www.ncbi.nlm.nih.gov/pubmed/12177785
http://dx.doi.org/10.1038/sj.bjc.6600479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376130/
https://www.ncbi.nlm.nih.gov/pubmed/12177785
http://dx.doi.org/10.1038/sj.bjc.6600479

Ejemplares similares